FertilityIQ DATA

The FertilityIQ Family Builder Workplace Index: 2019 -2020

Volume & Growth


According to the Centers for Disease Control and Prevention, infertility impacts approximately in 1 in 7 Americans. Every year since the 2008 economic downturn, the annual US volume of in-vitro fertilization (IVF) procedures (yellow bars) has increased and the year-over-year rate of growth (pink line) has accelerated in seven of the previous eight years, reaching an all-time high of 15% annual growth in the most recent year of national reporting.

Price & Growth


In 2018, we estimate the average fertility patient paid over $22,000 per “cycle,” with over 10,000 IVF patients reporting. This cost figure represents a 7% increase over 2017 and nearly a 15% increase since we began tracking the metric in 2015.

We estimate IVF cycle costs will hit $25,000 by 2025 abetted by greater use of genetic testing ($5,000), embryo storage costs ($500 - $1,000 per year), and broader adoption of financing options to pay for care (at 6 - 24% annual interest rates).

Cycles Per Patient & Affordability


Unfortunately, the vast majority of IVF cycles do not succeed and according to FertilityIQ data, more than half of patients must undergo a second cycle, and nearly a third of all patients undergo three or more treatments. As a result, it’s common for patients to spend upwards of $50,000 out of pocket on treatment, which roughly equates to the annual US household income of $51,000 (US Census data).

The vast majority of IVF patients treated in 2018 paid for most or all of their IVF treatment out-of-pocket, with little help from their insurance carriers, according to surveyed IVF patients treated in the trailing twelve months.

Historical Employee Perceptions of Fertility Benefits


The vast majority of fertility patients who receive IVF coverage through their employer report feeling a greater sense of loyalty and commitment to their employer as a result, which we uncovered in a survey of patients who received full coverage for their treatment cycles.

All the same, at companies that provide generous IVF coverage, employees give their employers poor marks when it comes to communicating about such programs and their details. We captured this in an earlier 2017 survey of over 1,000 verified IVF patients who had their treatment completely covered.

Summary of 2019 Findings


This year over 30,000 IVF patients were surveyed on their employers' — or their spouse’s employers' — 2019 fertility treatment policy. Patients reported over 400 US businesses and organizations had policies in place to cover the cost of IVF. What’s noteworthy about this year’s data is the degree to which:

  • Companies broadly implemented new or dramatically improved policies beyond what was covered in 2018. Approximately 23% of companies on this year’s list newly-implemented or substantially-enhanced their fertility benefit. For context, roughly 10% of companies listed in 2018’s report created or improved upon their offerings from 2017.

  • Fields like consumer product and retail, insurance, healthcare and industrial manufacturing drove nearly all of the above-mentioned gains in 2019. Fortune 100 companies like ExxonMobil (70,000 employees), Procter & Gamble (95,000 employees), AT&T (273,000 employees) and Liberty Mutual (50,000 employees) instituted new or enhanced benefits that resemble what’s been offered in the technology and consulting industries for years in terms of size, and accessibility.

  • Sectors like technology, consulting, and finance are shaping up to have a rather unremarkable 2019. Every bellwether in these fields already offers a benefit and with the exception of McKinsey & Company, most aren’t making any noteworthy improvements. Growth in the technology field largely comes from small, well-funded, still-private or recently-public businesses like Stripe, Lyft, Eventbrite and others.

  • Companies are beginning to remove “pre-authorization” requirements that historically prevented employees from accessing subsidized care quickly, or in the case of lesbian, gay or unpartnered employees, subsidized care at all. Noteworthy examples of companies mitigating, or altogether removing such pre-authorizations include Morgan Stanley (a rarity amongst investment banks), Sony Corporation, and S.C. Johnson.

  • A handful of consumer-facing companies that have weathered negative publicity in the face of the #metoo movement have newly-created, generous benefit packages, with Vice Media and Under Armour being the notable examples.

  • Starbucks is no longer the only large company (but still clearly the pioneer in) extending a fertility benefit to hourly, frontline workers. Businesses like Chobani now provide a $25,000 benefit to all employees, including the 75% of its workforce operating in the company’s factories.

Sector Breakdown


2019 is shaping up to be a breakthrough year for companies in the consumer product and retail, healthcare, insurance, and industrial spaces. Historically, benefit packages in these categories were uncommon and reimbursed at far lower rates than those provided by technology companies, investment banks, and consulting practices.

This year alone companies like ExxonMobil, AT&T, Procter and Gamble, Liberty Mutual, Tyson Foods, Northwestern Mutual, General Mills, and Geico, to name a few, have newly-introduced or dramatically upgraded their fertility benefit. These companies, along with a host of others, are now extending benefits that cover multiple IVF cycles and with few pre-authorizations required.

The implications of this are meaningful as each of these organizations employ upwards of 50,000 - 250,000 employees (well larger than their technology, consulting, or banking peers) and with few restrictions on access to care, and generous coverage, this trend could dramatically alter the volume and mix of hopeful parents able to build their families through IVF.

In sectors like consulting, banking, and technology, where fertility benefit penetration is high and packages are already rich (for example, Bain & Company, Boston Consulting Group, Bank of America, and Tesla all offer IVF packages with no dollar limit), 2019 appears headed to be a rather quiet year. There simply is little room for meaningful growth in these fields and aside from a possible loosening of pre-authorization restrictions for investment bank employees, we may not see much new development in the years to come.

Contrast this to years past where companies like Facebook, Google, Intel, and others dramatically upped their fertility benefits in an effort to attract talent. Within the technology field today, the noteworthy growth comes from the small, quickly growing cadre of companies (like Lyft, Stripe, Square, Stitchfix, and others) that are private or only recently became publicly-traded businesses. Many of these are still unprofitable businesses and are theoretically vulnerable to reconsider their policies should the economic tides shift, as many expect.

While a handful of large, nationally-recognized law firms instituted fertility treatment packages (and for the first time are starting to more closely resemble their consulting and banking peers), little progress was made in the non-profit, government, and higher education realm. This comes as little to surprise given many fear an economic downturn is on the horizon and no new major legislation has been passed to force cities, states, or universities to extend benefits.

Company Breakdown


This year we ranked companies based on two characteristics of their fertility benefit plan: the dollar amount for IVF procedure coverage and the extent to which employees must meet pre-authorization standards to actually access the benefit. These two criteria are used to calculate each organization’s “Point Total,” with a few notes:

  • Every dollar of IVF coverage corresponds to a point in the “Point Total”

  • Many companies do not specify a dollar amount of coverage but instead will cover a specific number of IVF cycles. Each IVF cycle covered equates to $22,000 of coverage and thus 22,000 points

  • For companies that provide an “unlimited” dollar amount of coverage, they are awarded 170,000 points

  • Companies that have minimal, or no, pre-authorizations are awarded an additional 20,000 points

Methodology


All information was provided by the 30,000+ members of the FertilityIQ community who’ve underwent IVF or by the companies themselves. Information on cost and treatment cycle numbers were provided by the 10,000+ FertilityIQ members who received IVF treatment in 2018.

Expert's Perspective
Dr de Ziegler's Guide To Endometriosis

Dr. de Ziegler breaks down the misconceptions around surgery being the only way to diagnose endometriosis, weighs in on the decision between IVF and endometriosis surgery, and much more.

Expert's Perspective
When Is The ERA Test Appropriate?

The Endometrial Receptivity Assay is a test used by clinicians to discern when an embryo should be transferred to the uterus. The developmental state of the embryo and the uterine lining must be in sync for the embryo to implant. Here we look at the theory behind the ERA's usefulness and what the data implies about who, if anyone, should have the test performed.

Expert's Perspective
Treating East Asian Women For Infertility

East Asian women may metabolize estorgen differently and this may be the reason their rates of success tend to lag those of Caucasian women. This may add insight on the woman's choice of a fresh versus frozen transfer or how much gonadatropins to take.

Expert's Perspective
How We Might Treat South Asian Women Differently

As a field we're beginning to appreciate that women of different ethnicities may require unique treatment to achieve comparable outcomes. Here, Stanford professor Val Baker eluciates some of the nuances in treating women of a South Asian background.

Expert's Perspective
How Long Are Frozen Eggs and Embryos Good For?

IVF treatment is a relatively new treatment, and egg and embryo freezing are newer still. So do we know how long these gametes can be safely stored and still work?

Expert's Perspective
The Male Fertility Evaluation: Enhances Options and Signals of Future Health

20 - 25% of U.S. couples annually undergo IVF without having the male partner properly checked. This drives tens of thousands of unnecssary treatments, as well as needless cost and suffering. What's more, bypassing this crucial step causes us to miss a vital signal into that man's future health.

Expert's Perspective
Is it safe to ship cryopreserved eggs (and embryos)?

Patients are increasingly eager to ship their eggs and embryos to clinics out of town, out of state and out of the country. Vitrification has made that a far more delicate process. Peter Nagy, Ph.D helps explain the outcomes, steps and costs associated with shipping gametes from one clinic to another.

Expert's Perspective
Freeze Eggs or Embryos?

When the option to freeze embryos is available to patients, many disregard the option to freeze eggs. Owen Davis, ASRM President, weighs in on why egg freezing is still an important option to consider.

Expert's Perspective
From MacBooks to MAC Cosmetics: How Our Daily Routine Impacts Fertility

Dr. Cooper lays out the evidence on the products & habits that harm fertility, and realistic steps we can take to protect ourselves

Expert's Perspective
Improving IVF Success Rates: Using Low Oxygen in the Lab

Selecting a clinic is as much about selecting their laboratory as anything else. A key determinant of lab quality is the conditions they use to culture embryos. Using low oxygen in the incubator is preferable, yet a third of laboratories don't do this.

Expert's Perspective
Early Pregnancy Loss

Early pregnancy loss is the only focus of the team at Montefiore-Einstein in NYC. Here are some of their high-level observations on how to deal with the medical challenges.

+ Show More Articles
Personal Story
What We Never Expected About Reciprocal IVF

Christina and her wife Katie decided to bulid their family using Reciprocal IVF. Christina walks us through what turned out how they expected, and what didn't -- including the financial costs, choosing sperm donors, IVF success (and failure), recognition by the state, and having the outside world accept them as equal mothers.

Personal Story
Getting it Together After the Diagnosis: Making a Plan With Your Partner

Laura and her wife Sam always presumed they would need treatment to have a child, but the news Laura had fertility issues came as a surprise. Over the course of multiple cycles, and multiple years, they learned a number of crucial lessons.

Personal Story
Marriage & Male Infertility: Not on the Same Page and That’s O.K.

Men and women often deal differently with the emotional impact of infertility. How important is it for us to see everything the same way?

Personal Story
Twiblings: Being Pregnant During Surrogacy

Some hopeful mothers fear that having a child through surrogacy will be less special or intimate. For those who wonder, meet Nancy Rohde, who carried her own child, and had a baby through surrogacy, at the same time.

Personal Story
Wrangling With Reduction

Many patients undergoing fertility treatment ultimately need to grapple with the notion of whether it is safe to have a multiple pregnancy. Katie Ferraro talks about her decision not to selectively reduce during her quadruplet pregnancy.

+ Show More Articles
Medical Research
What Mosaicism Means for Live Birth Rates

New data compares results transferring different types of mosaic embryos, with surprising outcomes.

Medical Research
IUI Success Rates Doubled With Endometrial Scratch

Medicated IUI success rates remain stubbornly low with live birth rates often around 10% per cycle. Investigators determined whether incorporating endometrial scratch bolsters IUI success rates. For the moment, it appears so.

Medical Research
The Impact of Sugar, Soda and Caffeine on IVF

The team at Brigham & Women's Hospital in Boston reveals surprising results on how sugar, soda and caffeine each impact (or don't) oocyte numbers and ultimate IVF success rates.

Medical Research
CRISPR, Gene Editing and IVF

Gene-editing in IVF made a big breakthrough this month and the CRISPR technology is now a reality. Here we catch up with Paula Amato and the team from Oregon Heath Sciences behind latest breakthrough.

Medical Research
The best starting point in treating PCOS? It’s not Clomid.

PCOS is responsible for 80% of cases where a woman isn't ovulting. A new study compared pregnancy success of clomiphene citrate (clomid) vs. letrozole (femara), with some strong results.

Medical Research
Weight Loss and IVF

The average American woman has a BMI in the high 20's. So for women undergoing IVF, with a BMI in the low-mid 30's, does weight loss improve rates of success? A team from Sweden ran a thoughtfully-conducted trial that offers up surprisingly complex answers.

Medical Research
IUI or IVF For Unexplained Infertility

Roughly 30% of infertility cases are labeled "unexplained," so how should patients decide between IUI vs IVF when we don't know the underlying issue? Here's one clue for a narrow subset of the newly-diagnosed "unexplained" population.

Medical Research
Does Your Clinic Influence If Your Embryos Are Good

Theoretically, the quality of your eggs and sperm should determine the quality of your embryos. However, this month we're reviewing data that shows which clinic you go to, and how they care for you and your embryos, could be a crucial determinant.

Medical Research
When IVF Babies Grow Up, Are They Healthy?

An Israeli study rigorously followed up with adults who were conceived via IVF, and compared their cognitive function, medical and mental health with naturally conceived peers. This is a unique study focusing on the long-term health of IVF babies and adults.

Medical Research
When One IVF Cycle Completes All Your Family Building Goals

For some IVF patients a single cycle can deliver two children through two pregnancies. For many Americans, two children is the ideal number. So who are the best candidates for "one-and-done" IVF in a safe and responsible manner?

Medical Research
Why It Matters Which Doctor Performs Your IVF Transfer

According to FertilityIQ data, 70% of patients have a different doctor perform their transfer. Scott Morin and Eric Forman of RMA New Jersey study to what extent that matters.

+ Show More Articles